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Rapport de synthèse 
L'hyperplasie intimale est la cause majeure de sténoses de pontages veineux. Différents médicaments 
tels que les statines permettent de prévenir les sténoses mais leur administration systémique n'a que peu 
d'effet. Nous avons développé une matrice d'hydrogel d'acide hyaluronique qui permet d'avoir un 
relargage contrôlé d'atorvastatine sur un site désiré. 
L'enjeu de ce projet de recherche est de démontrer que l'atorvastatine relarguée par l'hydrogel a un effet 
similaire sur les cellules musculaires lisses de veines saphènes humaines comparé à l'atorvastatine 
directement diluée dans le milieu de culture. 
La recherche a été conduite conjointement par le laboratoire de médecine expérimentale du département 
de chirurgie thoracique et vasculaire du Centre Hospitalier Universitaire Vaudois et de !'Ecole de sciences 
pharmaceutiques des Universités de Lausanne et de Genève. 
On a incorporé de l'atorvastatine calcium (Chemos GmbH, Regenstauf Allemagne) dans des gels d'acide 
hyaluronique (Fortelis extra) à des concentrations déterminées afin de pouvoir analyser le relargage de 
l'Atovastatine dans le milieu de culture cellulaire par rapport aux concentrations d'atorvastatine 
directement ajoutées dans le milieu. 
Des cellules musculaires lisses primaires ont été cultivées à partir d'explants de veines saphènes 
humaines. Elles ont été identifiées grâce à l'immunohistochimie par des anticorps contre la desmine et 
l'alpha-smooth muscle actine. 
La prolifération et la viabilité de ces cellules ont été analysées à l'aide du test MTT, leur transmigration 
avec le test de la chambre de Boyden et leur migration avec le principe de cicatrisation de plaies (wound 
healing assey). 
L'expression de gènes connus pour participer au développement de l'hyperplasie intimale, tels que la gap 
junction protein Connexin43 (Cx43), l'inhibiteur du plasminogène PAl-1, l'hème oxygénase H0-1, la 
métalloproteinase-9 et l'inhibiteur de l'activateur du plasminogène tissulaire tPA, a été déterminée par 
niveau de mRNA exprimé en PCR. Leur expression en protéines a été analysée en utilisant la méthode 
par Western blots ainsi que l'immunohistochimie. 
Les expériences ont été effectuées à triple reprise en duplicats en parallèles avec de l'atorvastatine 
calcium directement ajoutée dans le milieu de culture et avec l'atorvastatine relarguée par l'hydrogel 
d'acide hyaluronique. 
Conclusions 
L'atorvastatine est relarguée par l'hydrogel de façon contrôlée. 
L'hydrogel contenant l'atorvastatine diminue la viabilité et la transmigration des cellules musculaires 
lisses de veines saphènes humaines de façon similaire à l'atorvastatine directement introduite dans le 
milieu de culture. 
L'hydrogel contenant l'atorvastatine module de façon sélective l'expression de marqueurs de la 
différentiation cellulaire de cellules musculaires lisses de veines saphènes humaines avec un retard de 
24 heures comparé avec les effets de l'atorvastatine directement ajoutée au milieu de culture, sans 
néanmoins changer la distribution intra-cellulaire des protéines Cx43, H0-1 et PAl-1. 
Perspectives 
Il s'agit d'un projet d'importance clinique majeure permettant de réaliser des améliorations du traitement 
des artériopathies occlusives, ainsi que de relevance pharmacologique permettant de réaliser des dépôts 
de molécules avec·Em relargage stable et contrôlé à un site spécifique. 
JPET Fast Forward. Published on September 26, 2013 as 001:10.1124/jpet.113.208769 
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ABSTRACT 
Intimai hyperplasia (IH) is the major cause of stenosis of vein grafts. Drugs such as 
statins prevent stenosis but their systemic administration has limited affects. We 
developed a hyaluronic acid hydrogel matrix which ensures a controlled release of 
atorvastatin (ATV) at the site of injury. The release kinetics demonstrated that 100% of 
ATV was released over 1 O h, independently of the loading concentration of the 
hydrogel. We investigated the affects of such a delivery on primary vascular smooth 
muscle cells isolated from human veins (HSMCs). ATV decreased HSMCs proliferation, 
migration and passage across a matrix barrier in a similar dose- (5 -1 O µM) and time-
dependent manner (24-72 h), whether the drug was directly added to the culture 
medium or released from the hydrogel. Expression analysis of genes known to be 
involved in the development of IH, demonstrated that the transcripts of both the gap 
junction protein Connexin43 (Cx43) and the plasminogen inhibitor PAl-1 were 
decreased after a 24-48 h exposure to the hydrogel loaded with ATV, whereas the 
transcripts of the heme oxygenase H0-1 and of the inhibitor of tissue plasminogen 
activator tPA were increased. At the protein level, Cx43, PAl-1 and the 
metalloproteinase-9 expression were decreased, whereas H0-1 was upregulated in the 
presence of ATV. The data demonstrate that the ATV released from a hydrogel has 
similar affects on HSMCs than the drug freely dissolved in the environment. 
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INTRODUCTION 
Open surgical revascularization is still frequently the best option to treat coronary, lower 
limbs or cerebrovascular occlusive disease. Nevertheless, restenosis is a major reason 
of failure in 20 to 50% of these grafts, leading to the partial or complete occlusion of the 
anastomosis sites (Hwang et al., 2011 ). Post-vascular intervention stenosis results 
mainly from intimai hyperplasia (IH) (Hwang et al., 2012; Shah et al., 2003), i.e. the 
thickening of the tunica intima due to proliferation of vascular smooth muscle cells 
(VSMCs), and from arterial remodeling, i.e. the rapid alteration of vein grafts implanted 
into the arterial circulation (Ward et al., 2000). IH is an adaptative process taking place 
in response to hemodynamic stresses and injuries, and which occurs following bypass 
graft interventions on arteries, veins and artificial prosthesis (Sugimoto et al., 2009; 
Zalewski et al., 2002). lt is characterized by the hyperproliferation and migration of 
VSMCs into the sub-intimal region and by an increase in matrix proteins which, 
together, thicken the tunica intima (Newby, 1997) at the site of injury. This biological 
cascade is the main trigger of the dedifferentiation of the poorly proliferating, contractile 
VSMCs into fast proliferating cells secreting extracellular matrix (Alexander and Owens, 
2012; Nguyen et al., 2013). 
Drugs preventing intraluminal vessel narrowing have been previously identified using an 
endovascular platform, such as a stent or a plain balloon (Schachner et al., 2006; 
Wiedemann et al., 2012). However, when open revascularization is mandatory, no 
platform is available for the local delivery of a drug. Thus, current freatments involve the 
repeated systemic administration of the active compound, which markedly increases its 
side affects (Wiedemann et al., 2012). These problems may be decreased by a local 
application of q,drug depot at the site of the surgery. ldeally, such a biocompatible depot 
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should sustain a controlled and stable release of the active drug for a time sufficient to 
revert the phenotype of altered VSMCs, and be biodegradable, to avoid the need of a 
second surgery for its elimination. Here, we have investigated a hyaluronic acid 
hydrogel matrix, which can be loaded with a variety of drugs known to inhibit the 
proliferation and migration of vascular smooth muscle cells, as well as the inflammation 
of the vesse! wall (Baek et al., 2012a; Baek et al., 2012b). Among these drugs, the 
HMG-CoA reductase inhibitors statins, have been shown to be fairly effective in 
preventing post-surgery stenosis (Qiang et al., 2012). However, the systemic 
administration of statins has limited effects on this prevention (Stettler et al., 2007), and 
undesirable side effects have been reported (Taylor et al., 2013). Therefore, we tested 
the effect of atorvastatin (ATV) after loading in a hyaluronic acid hydrogel on the 
proliferation, migration and invasiveness of primary smooth muscle cells derived from 
human saphenous veins. The data document that the hydrogel is a suitable support for 
the local delivery of drugs, inasmuch as it allowed for the stable release of ATV during 
hours, which resulted in several modifications of the VSMCs phenotype, alike those 
induced by the drug freely dissolved in the cell environment. 
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MATERIAL AND METHODS 
Preparation of the atorvastatin-loaded hydrogel 
Hyaluronic acid gels (Fortélis extra®), consisting of 25.5 mg/ml crosslinked hyaluronic 
acid obtained from biofermentation and suspended in phosphate butter, were 
generously given by Anteis (Anteis SA Rue de Veyrot 11, 1217 Meyrin, 
Geneva/Switzerland Meyrin, CH) and were used as received. Calcium atorvastatin 
(ATV) obtained from Chemos GmbH (Regenstauf, Germany) was dissolved in 33% 
ethanol aqueous solution and incorporated by gentle stirring. in the hydrogel at the 
desired concentration. The gel was freeze-dried in a Telstar LyoBeta 15 (Telstar, 
Terrassa, Spain) using a primary drying at -40°C under 0.2 mBar for 1 h, followed by a 
1 o h secondary drying at 20°c to eliminate bath alcohol and water. lt was then 
reconstituted to the initial volume with sterile MilliQ water over a period of 24 h. This 
rehydratation restored the macroscopic transparency and viscosity of the unloaded gel, 
which could be easily disposed with a syringe. For cell culture experiments, the 
preparation was made under sterile conditions in a laminar flow (Steag LFH07.15, 
Luftechnik+Metallbau AG, Wettingen, CH), using autoclaved materials. 
1 n vitro release of A TV 
The in vitro release of ATV was determined under sink conditions. To this end, 1 OO µI 
ATV-loaded hydrogel were placed in the 24 wells of a cell cultur.e plate, and covered 
with a dialysis membrane with a eut off of 14 kDa (Merck, Darmstadt, Germany), which 
was maintained in place using a silicon 0-ring. 500 µI RPMI 1640 (life technologies) 
culture medium (RPMI) supplemented with 10% fetal calf serum (FCS) and 1 % 
penicillin/streptomycin were added to each well. At defined time intervals, 200 µI 
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medium were sampled, and replaced with the same volume of fresh medium. Samples 
were extracted with 300 µI acetonitrile, and analyzed by HPLC-UV to determine the 
ATV concentration. The HPLC system consisted of a Waters LC Module 1 (Waters 
Corporation, Milford, MA, USA) and a Nucleosil, 125/4, 100-5 Cm column (Macherey-
Nagel, Switzerland). The mobile phase (acetonitrile/1 O mM pH 3 acetate butter: 55/45) 
was delivered at a flow rate of 1 ml/min. The method has been fully validated and a 
Limit of Quantification (LOO value) of 500 ng/ml and a Limit of Detection (LOD value) of 
50 ng/ml were obtained. A trueness of 98-102% was determined and the intermediate 
precision was < 2%; moreover, the three replicates injected at three different days 
demonstrate the repeatability of the method. The injection volume was 20 µI, and the 
drug was detected at 245 nm. A standard plot of ATV concentrations ranging from 6.25 
to 50 µg/ml was prepared under identical conditions. Release profiles were compared 
using the similarity factor f 1 and difference factor f2 (U.S. Food and Drug Administration. 
Guidance for industry CMC5-1995: immediate release solid oral dosage forms, 1995) 
(Shah et al., 1998). Equivalent profiles show f 1 value close to O (generally less than 15) 
and f2 value close to 1 OO (generally greater than 50). Three independent experiments 
were run. 
Cell culture 
Samples of human saphenous veins were obtained from patients undergoing peripheral 
artery bypass surgery, and prepared for explants culture, as previously described 
(Corpataux et al., 2005a; Corpataux et al., 2005b). Primary smooth muscle cells were 
cultured from human saphenous veins from 23 different patients, predominantly male 
(82%) with a mean age of 68.2 +/- 12, 1 years. The Ethical Committee of the University 
of Lausanne approved the experiments, which are conform with the principles outlined 
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in the Declaration of Helsinki for use of human tissue. Briefly, vein segments discarded 
at surgery were placed in RPMI medium. Adhering fat and connective tissue were 
discarded. The adventitia was carefully removed, and the vessel was opened 
longitudinally. The inner surface was scraped to remove endothelial cells. Veins 
explants of 1-2 mm were plated, luminal side down, on the dry surface of a 12-well 
culture plate. Explants were gently covered with one drop of RPMI medium, and placed 
overnight in a 37°C incubator gassed with air/5% C02. The next day, culture medium 
was carefully added to the wells, taking care not to detach the explants. Medium was 
changed every 2-3 days for 1-2 weeks, till cells started to migrate out from the explants. 
Smooth muscle cells (HSMCs) were identified by immunostaining using antibodies to a-
smooth muscle actin (abcam, ab5694) and desmin (Dako, M 0760). Primary 
proliferating HSMCs, which featured a doubling time of 72-96 h, were grown to 
confluence, passed once per week, and cultured until passage 3. 
Cell proliferation 
12500 HSMCs were seeded per well in a 24-well plate and incubated in RPMI 1640 
containing 0.4% FCS (growth arrest medium) for 24 h. The next day, the growth arrest 
medium was removed and replaced with 600µ1 RPMI 1640 containing 10% FCS 
supplemented with ATV (5µM or 10 µM). To evaluate the effect of ATV release by 
hydrogel, only 500 µI RPMI 1640 were added and 1 OO µI of ATV-loaded hydrogel (5µM 
or 1 O µM) or unloaded hydrogel were placed within a transwell insert of 8 µm pore 
polycarbonate membrane (Falcon). Cell viability was assessed by the MTT test (Chen 
et al., 2011; Loo et al., 2011; Wang et al., 2011) prior to the addition of ATV or ATV-
loaded gel (time 0), and after 24, 48, and 72 h of culture. To this end, the cells were 
incubated with ,40 µI MTI labeling solution (5 mg/ml) in 200µ1 medium at 37 °C for 4 h, 
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and then solubilized in 200 µI DMSO (Dimethyl sulfoxide). Absorbance at 570 nm was 
measured with a microtiter plate reader with a reference wavelength of 630 nm, the 
reaction solvent being used as a blank. 
Cell transmigration 
The chemotactic-induced transmigration of HSMCs across a matrix barrier was 
investigated using a Boyden chamber (Back et al., 2005; Corpataux et al., 2005a; 
Corpataux et al., 2005b; Erices et al., 2011 ), made of a polycarbonate membrane insert 
with 8-µm pores-(Falcon) placed in 24-well tissue culture plates. Confluent HSMCs 
were trypsinized and suspended in RPMI 1640 containing 10% serum supplemented 
with 0.25% bovine serum albumin and 50 ng/ml Platelet-Derived Growth Factor 
(PDGF) (migration medium). 105 HSMCs in 500 µL migration medium supplemented 
with various concentrations of ATV (5µM or 10 µM) were loaded into the upper well of 
each chamber. ln the experiments testing the delivering system, 1 OOµI of hydrogel (5µM 
or 10 µM ATV) deposited on the bottom of wells and covered with a dialysate 
membrane (Aldrich 09527, MWCO 12 kDa) fixed by a rubber band were preincubated 
during 24 h in the presence of 500 µL RPMI 1640 which was supplemented with 10% 
FCS, 0.25% bovine serum albumin and 50 ng/ml PDGF prior to be used for the 
transmigration experiments. After a 24 h culture at 37°C, the cell suspension was 
removed from the top of the inserts, which were washed with phosphate-buffered saline 
(PBS) and fixed in 100% ethanol at -20°c for 30 min. The upper side of the membranes 
was then rubbed with a moist cotton swab and a spatula to remove the cells which did 
not transmigrate and the membranes were stained for 1 O min with hematoxylin, washed 
in PBS and examined under a x400 light microscope for scoring the nuclei of migrating 
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HSMCs. transmigration was expressed as the mean number of migrated cells per high 
power field. 
Cell migration 
Cell migration was studied by a wound healing assay (Chen et al., 2011; Erices et al., 
2011 ), using silicon culture inserts (lbidi®) which define a cell free gap of 500 µm. 
15000 HSMCs in 70 µI migration medium were seeded on both sides of the insert. After 
24 h, when cells reached a 90% confluence, the inserts were removed and the HSMCs 
were overlayed with 600µ1 of culture medium supplemented with different 
concentrations of ATV. For the experiments involving the delivering system, 1 OO µI of 
hydrogel were overlaid in a transwell insert made of a polycarbonate membrane with 8 
µm pore-size (Falcon), which was placed in the wells of a 24-well plate, containing 500 
µI migration medium. Cultures were photographed at time 0, just after the silicone insert 
was removed, and thereafter every 12 h for a period of 48 h. Cells that migrated in the 
500 µm area initially defined by the silicone insert were counted under a light 
microscope, at a magnification of x350. 
Transcript analysis 
The levels of human Connexin43 (Cx43), heme-oxygenase-1 (H0-1 ), tissue 
Plasminogen Activator (tPA) and plasminogen activator inhibitor-1 (PAl-1) mRNA were 
determined by quantitative reverse transcription PCR, using the Fast SYBR® Green 
Master Mix (Applied Biosystems) in a ViiA™7 Instrument (Applied Biosystems). Briefly, 
RNA extracted from HSMCs using TriPure isolation reagent (Roche), was treated for 30 
min in the presence of DNase 1 (DNA-free kit, Ambion, Cambridge, UK). One µg total 
RNA was useq: for reverse transcription (Promega, Madison, Wise., USA). Equivalent 
13 
JPET #208769 
amounts of cONA from each reaction were processed for RT-PCR analysis. Negative 
contrais included amplification of distilled water, and RNA samples which had not been 
reverse transcribed. The primers used to amplify specific cONAs are given in Table 1, 
and were designed using the free on li ne software Primer3 
{http://frodo.wi.mit.edu/primer3D (Alonso et al., 2010a; Alonso et al., 201 Ob). 
Western Blots 
HSMCs were washed once with cold PBS and immediately collected and homogenized 
in lysis butter containing SOS as published (Alonso et al., 201 Oa; Alonso et al., 2010b). 
Protein content was measured using a detergent-compatible OC protein assay kit (Bio-
Rad Laboratories, Reinach BL, Switzerland). Samples of total cell extracts (15 µg) were 
resolved by SOS-PAGE (10 %) and transferred to a PVOF membrane {lmmobilon p, 
Millipore). Membranes were incubated for 1 h in PBS containing 5% milk and 0.1 % 
Tween20 (blocking butter). Saturated membranes were incubated overnight at 4°C in 
blocking butter containing monoclonal anti-Heme Oxygenase 1 antibodies (ab13248 
diluted 1 /500, Abcam), rabbit polyclonal anti-Cx43 antibodies (AB1728 diluted 1 /1000, 
Millipore), rabbit polyclonal anti-MMP9 antibodies (ab38898 diluted 1 /500, Abcam), 
rabbit polyclonal anti-PAl-1 antibodies (NBP1-19773 diluted 1/1000, Novus Biologicals) 
or monoclonal antibodies anti-alpha-tubulin (T5168, diluted 1 :3000, Sigma-Aldrich). 
After incubation at room temperature for 1 h with a relevant secondary antibody 
conjugated to horseradish peroxidase (Fluka Charnie, diluted 1 :20,000), membranes 
were revealed by enhanced chemiluminescence (ECL) according to the manufacturer's 
instructions (Amersham Bioscience Europe). Oensitometric analyses of immunolabeled 
proteins were performed using the lmageQuant Software (Molecular Oynamics, 
Amersham Bio~9ienceEurope). 
14 
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lmmunocytochemistry 
HSMCs grown to confluence on glass slides; were fixed for 1 O min in acetone at -20°C, 
air-dried, rinsed in PBS, and permeabilized for 1 h in PBS supplemented with 1.5% BSA 
and 0.1 % Triton X-1 OO. The cells were incubated overnight at 4°C in the presence of 
either a rabbit antibody against Cx43 (3512, 1 /1 OO, Cell Signaling), a monoclonal 
antibody against Herne Oxygenase 1 antibody (ab13248, 1 /50, Abcam) or a rabbit 
antibody against PAl-1 (NBP1-19773, 1/50, Novus Biologicals). Cells were washed and 
further exposed for 1 h at room temperature to an appropriate Alexa fluor 488 or 594-
conjugated antibodies (1 /1000; N. V. lnvitrogen SA). Cells were then washed, mounted 
in PBS containing 50% glycerol and 0.4 µg/ml DAPI, and photographed under 
fluorescence microscopy (Leica Camera AG, Nidau, Switzerland). 
Statistical analysis 
Data are presented as mean values are given ±SEM. One-way ANOVA was performed 
to compare the mean values between groups, using the post-hoc Bonferroni test, as 
provided by the Statistical Package for the Social Science (SPSS 17.0, Chicago, IL). A 
P value< 0.05 was considered as significant. 
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RESULTS 
Atorvastatin is released from the hydrogel in a controlled manner 
The hydrogel released the entire amount of loaded ATV in the cell culture medium 
over 1 O h (Fig. 1 A) whatever the initial concentration, as indicated by a similarity factor 
fa =62 and a difference factor f1=5.9. Therefore, the shape of the release curve did not 
depend on ATV concentration, within the concentration range (2.5-10 µM) studied. ln 
contrast, the release of ATV per hour increased with the initial concentration of the drug 
(Fig. 1 B), resulting in significantly different release profiles (f 1<15 and f2>50 for all pair 
comparisons). The data show that the release of ATV from the hydrogel is sustained 
and controlled. 
The atorvastatin-loaded gel decreases the viability of HSMCs 
The viability of HSMCs increased with time in medium devoided of ATV or containing a 
drug-free hydrogel, as revealed by the MIT test (Fig. 2). A similar pattern was seen 
when HSMCs were cultured in the presence of 2.5 µM ATV (not shown). ln contrast, the 
addition of 5-1 O µM ATV to the culture medium significantly decreased this viability (Fig. 
2). A similar decrease was observed with HSMCs cultured in the presence of an ATV-
loaded hydrogel (Fig. 2). This decrease reached significance after 24 h and 72 h culture 
in the presence of 10 and 5 µM ATV, respectively. From these observations, we choose 
to test these two concentrations in all further experiments. The results indicate that ATV 
interferes with the viability of HSMCs, and that this effect is not altered when the drug is 
released by a hydrogel. 
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The atorvastatin-loaded hydrogel decreases the transmigration of HSMCs 
Control HSMCS rapidly transmigrate across an artificial membrane (Fig. 3). A 
significant decrease in this ability was observed after exposure to 5-1 O µM ATV, 
whether the drug was directly added to medium or was released by a hydrogel (Fig. 3). 
At the same concentrations, ATV, also reduced the migration of HSMCs, as assessed in 
a wound healing assay (Fig. 4). A significant change was observed faster in the 
presence of 10 µM (24 h) than 5 µM ATV (36 h) (Fig. 4). The data document that the 
drug released by the hydrogel significantly affected the in vitro function of HSMCs. 
The atorvastatin-loaded hydrogel selectively modulates the expression of 
markers of HMSCs differentiation 
ATV decreased the expression by HSMCs of Connexin43 (Cx43), the 
metalloproteinase-9 (MMP9) and plasminogen activator inhibitor PAl-1, two markers of 
IH (Berard et al., 2013; Deglise et al., 2005)· at both transcript (Fig. 5) and protein levels 
(Figs. 6 and 7). ln contrast, the expression of the heme oxygenase H0-1 (Lee et al., 
2004) and the tissue plasminogen activator tPA (Berard et al., 2011; Saucy et al., 2010) 
were up-regulated by ATV (Figs. 5-7).These changes were observed whether ATV was 
directly added to the medium or was released by a hydrogel, but, in the latter condition, 
became significant with a delay of about 24 h compared to the former condition (Figs. 
5-7). lmmunofluorescence showed that, in spite of these quantitative changes, ATV did 
not alter the intra-cellular distribution of the Cx43, H0-1 and PAl-1 'proteins (Fig. 7). 
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DISCUSSION 
The implantation of a vein graft into the arterial circulation often results in the 
development of intimai hyperplasia (IH), leading to vesse! stenosis (Owens, 201 O; 
Owens et al., 2009). This process is associated with the dedifferentiation of HSMCs, 
which turn from a contractile to a secretory phenotype, characterized by increased 
proliferation and migration (Alexander and Owens, 2012; Mitra et al., 2006; Nguyen et 
al., 2013; Owens et al., 2004). Given that IH involves various biological mechanisms, a 
therapy combining different drugs may help interfering with the vessel stenosis. 
Candidates, such as statins, have limited effects after systemic administration, due to 
liver catabolism, digestive clearance and frequent side effects at the high dosage 
required for systemic efficiency. lt would be beneficial to selectively provide the drugs at 
the site of the stenosis (Wiedemann et al., 2012). As yet, however, no method can 
achieve such a locally targeted therapy. 
As a first approach towards such development, we investigated a hydrogel platform that 
could ensure a local and controlled delivery of statins in a surgical field. Various 
thermosensitive gels have been tested for drug administration that, however, usually 
have a rather short residence time in vivo (Le Renard et al., 2010). We have selected a 
hydrogel made of hyaluronic acid, a key component of extracellular matrix in most 
native tissues, for two reasons. First, the crosslinking of hyaluronic acid increases the 
gel viscosity, extending its in vivo persistence (Eider et al., 2011 ). Second, hyaluronic 
acid could help reduce IH formation (Chajara et al., 2003; Ferns et al., 1995). Here, we 
have tested such a gel for the delivery of atorvastatin (ATV), a statin which inhibits 
HSMCs proliferation (Corpataux et al., 2005a; Corpataux et al., 2005b), and IH (Qiang 
et al., 2012). 
": 
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Using primary HSMCs from human saphenous veins, we demonstrate that ATV 
decreases the viability, the proliferation and the transmigration of HSMCs, and that 
these effects were similarly observed whether the drug was directly added to the culture 
medium or was loaded on the hyaluronic acid hydrogel. The difference between the two 
conditions only related to the time course. Thus, the effects of the ATV hydrogel were 
somewhat delayed compared to those of the free ATV, and were sustained for the 48 h 
which were investigated here. This time frame should provide a sufficient therapeutic 
window to interfere with the early steps of IH development, which is launched by the 
endothelium disruption. The administration of 80 mg ATV results in a maximum plasma 
concentration of the active molecule of about 50-200 ng/ml after 1-2hours (Bahrami et 
al., 2005), i.e. concentrations which are significantly lower than those we tested (2.5 - 5 
µM) and could explain partially the limited effect of atorvastatin taken orally. The latter 
concentrations, which were aimed to reach a range of those which are usually tested in 
vitro (Saijonmaa et al., 2004; Suski et al., 2013) are essential to reach a high local 
concentration of the drug. The need of elevated concentrations to detect functional 
effects of ATV in vitro is also likely due the higher proliferation of SMC in culture, which 
contrast with their usually quiescent state in vivo. Moreover, the continuous stimulation 
of SMC with the serum, growth factors and nutrients of culture media could participate 
to the desensitization of cells to lower concentrations of ATV. At any rate, these 
concentrations differences do not undervalue the interest of our experimental 
observations, which were all made under rigorously similar conditions for control SMC 
and ce lis exposed to A TV. 
We also document that ATV differentially regulates the expression of specific genes 
involved in the development of IH, decreasing Cx43, MMP-9 and PAl-1, and raising tPA 
and H0-1. By jmmunofluorescence studies, we further demonstrated that the levels of 
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Cx43, were time dependently decreased in the presence of both free ATV or ATV 
release from hydrogel, whereas those of H0-1 and tPA were increased under the very 
same conditions. Vascular cells express 4 connexins (Cx37, Cx40, Cx43 and Cx45) in 
various amounts depending on species and vascular beds (Alonso et al., 201 Ob). These 
proteins appear involved in different aspects of IH. Thus, we previously demonstrated 
that Cx43 is expressed in HSMCs of human veins, and is upregulated in the media layer 
with the development of IH (Deglise et al., 2005). Cx43 participates to control the 
migration and proliferation of HSMCs (Song et al., 2009), and is increased with the 
synthetic state of these cells, which develops in early atherosclerotic lesions (Haefliger 
et al., 2004). Moreover, statins reduced Cx43 in the aortas of atherosclerotic rabbits 
(Wang et al., 2005). Herne oxygenases (HO) degrade heme to biliverdin, carbon 
monoxide (CO) and free iron (Otterbein et al., 2000; Otterbein et al., 2003). The 
exogenous administration of H0-1 reduced the development of atherosclerosis, and 
restenosis in balloon-injured rat models (Juan et al., 2001; Tulis et al., 2001 ). 
Simvastatin increased the cytoprotective H0-1 in HSMCs (Lee et al., 2004), partially 
accounting for its anti-inflammatory effects (Lee et al., 2004). IH remodeling requires the 
integrated effects of the fibrinolytic system, the matrix metalloproteinases (MMPs), and 
their inhibitors. We recently showed that Plasminogen Activator lnhibitor 1 (PAl-1) (Ha 
et al., 2009) is induced by arterial shear stress, and promotes IH (Berard et al., 2013), 
likely by enhancing the degradation of the extracellular matrix, which facilitates the 
migration of HSMCs from the media to the intima layer (Muto et al., 2012). lt is 
remarkable that several of the factors which contribute to IH, are simultaneously but 
differentially regulated by ATV, in a way that interferes with the pathological remodeling 
of the vascular wall. 
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Would the drug, and other candidate statins, be made selectively available at the site of 
venous stenosis, it may be feasible to prevent or hinder IH, if the effective drug levels 
can be maintained for the few early days during which the phenotypic change of 
HSMCs is launched. Our experiments indicate that this can be achieved, at least in 
vitro, using a hydrogel of native hyaluronic acid, which releases active ATV in a 
sustained way. The results open the way towards the generation of further platforms 
that could release a combination of anti-stenosis drugs, in vivo and over extended 
periods of time. 
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FIGURES LEGENDS 
Figure 1: Atorvastatin is released by the hydrogel in the cell culture medium 
Upper panel: The kinetic of A TV release is independent of the initial loading 
concentration. Lower panel: ln contrast, the amount of ATV released per h increased 
with the concentration of the drug. Mean values are given ±SEM (n=3). 
Figure 2: The atorvastatin-loaded hydrogel decreased the viability of HSMCs 
The viability of HSMCs, as assessed by the MTT test, was significantly reduced by 5-10 
µM ATV, whether the drug was added directly to the culture medium (Medium) or was 
released by a hydrogel (Gel). This change was faster (24h) in the presence of 1 O µM 
than 5 µM ATV (72h) *P < 0.05, versus the respective cells incubated in absence of 
ATV (contrai). 
Figure 3: The atorvastatin-loaded hydrogel decreased the transmigration of 
HSMCs 
Upper panel: Transmigration of HSMCs in presence or absence of of ATV was 
assessed with the modified Boyden chamber technique. 
Lower panel: Quantitative assessment of the transmigrated cells demonstrate a 
significant decrease in the capacity of HSMCs to transmigrate in presence of ATV in 
medium or released from the hydrogel. *P < 0.05, **P < 0.01 and ***P < 0.001 versus 
contrai cells incubated in absence of ATV. Bar represents 20 µm. 
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Figure 4: The atorvastatin-loaded hydrogel decreased the migration of HSMCs 
Upper panel: Primary HSMCs migration was assessed using silicon culture inserts 
defining a cell free gap ~500 µm (lines). HSMCs grown under control conditions (control 
medium) migrated into this gap to fill it in about 48h. This migration was decreased by 5 
and 10 µM ATV, whether the drug was added directly to the medium (ATV medium) or 
was released by the hydrogel (ATV gel). Bar represents 80 µm. 
Lower panel: Inhibition of cell migration was observed at 36 h in the presence of 5 µM 
ATV, and already at 24 h in the presence of 1 O µM ATV directly added to the culture 
medium (left panel). A similar inhibition of HSMCs migration was observed using the 
ATV-loaded hydrogel (right panel). *P < 0.05, **P < 0.01, ***P < 0.001 versus control 
cells incubated in the absence of ATV. 
Figure 5: Atorvastatin regulates the levels of selective transcripts of HSMCs 
After a 24h exposure to ATV directly added to the medium, the expression of PAl-1 and 
Cx43 mRNA was decreased, whereas that of tPA and H0-1 transcripts was increased. 
Twenty four hours later, similar changes were detected in HSMCs exposed to ATV 
released from the hydrogel. *P < 0.05, **P < 0.01 and ***P < 0.001 versus cells 
incubated in absence of ATV (Control). 
Figure 6: Atorvastatin regulates the levels of selective proteins of HSMCs 
HSMCs cultured for 24 h in a medium supplemented with ATV showed decreased 
expression of the PAl-1, MMP9 and Cx43 proteins, but increased levels of the H0-1 
protein. Similar changes were observed 24 h later, in cells exposed to an ATV-loaded 
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hydrogel. *P < 0.05, **P < 0.01 and ***P < 0.001 versus cells cultured in the absence of 
ATV (Control). 
Figure 7: ATV did not perturb the intracellular localization of the proteins it 
quantitatively regulated 
lmmunocytochemistry confirmed the decreased expression of Cx43 and PAl-1, and the 
increased expression of H0-1 in HSMCs exposed to ATV and further revealed that 
these changes did not affect the distribution of these proteins. Thus, in both control and 
ATV-treated cells, Cx43 was mostly distributed at the cell membrane, whereas PAl-1 
and H0-1 were largely observed within the cytoplasm. 
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Table 1: Human primers for quantitative real-time PCR 
Gene 
PAl-1 
Cx43 
H0-1 
tPA 
GAPDH 
Sense primer (5'-3') 
GGCTGGTGCTGGTGAATG 
GAACTCAAGGTTGCCCAAAC 
AGGAGGTCATCCCCTACACA 
ACACAGCACAGAACCCCAGT 
AACTTTGGTATCGTGGAAGG 
Antisense primer (5'-3') 
ATCGGGCGTGGTGAACTC 
TTAGAGATGGTGCTTCCC 
GGGGTAGAGCTGCTTGAACT 
CAGGAGGGCACATCACAGTA 
CAGTAGAGGCAGGGATGATGT 
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